Newman Ferrara LLP Announces Corporate Governance Investigation of Abeona Therapeutics Inc. – ABEO
June 18 2018 - 4:21PM
Business Wire
Newman Ferrara LLP announced today that the firm is conducting
an investigation on behalf of stockholders of Abeona Therapeutics
Inc. (“Abeona” or the “Company”) (NASDAQ: ABEO) into potential
breaches of fiduciary duty by the Company’s Board of Directors (the
“Board”).
Abeona, headquartered in Dallas, Texas, is a clinical-stage
biopharmaceutical company that develops gene therapy products for
rare diseases. Newman Ferrara’s investigation focuses on decisions
made by the Board, without shareholder approval, the result of
which significantly diminish shareholder value and do not benefit
the Company. Considering the Abeona’s poor performance and mounting
losses, it is clear that the Board lacks the ability to fairly
assess and oversee the Company’s direction and leadership.
Current Abeona stockholders seeking more information on this
matter are invited to contact Newman Ferrara attorneys Jeffrey
Norton (jnorton@nfllp.com) or Ryan Jerome (rjerome@nfllp.com) to
discuss this investigation and their rights.
Newman Ferrara maintains a multifaceted practice based in New
York City with attorneys specializing in complex commercial and
multi-party litigation, securities fraud and shareholder
litigation, consumer protection, civil rights, and real estate. For
more information, please visit the firm website at
www.nfllp.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180618006156/en/
Newman Ferrara LLPJeffrey M. Norton,
212-619-5400jnorton@nfllp.com
Abeona Therapeutics (NASDAQ:ABEO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Abeona Therapeutics (NASDAQ:ABEO)
Historical Stock Chart
From Apr 2023 to Apr 2024